Lykos said it has appointed Allison Rosenthal as chief commercial officer and Coy Stout has joined the company as VP of market access.
Lykos Therapeutics said it has appointed Allison Rosenthal as chief commercial officer and member of the company’s executive committee, effective immediately.
Lykos – formerly known as MAPS PBC – also announced that Coy Stout has joined the company as vice president of market access.
“The appointment of Allison, our first chief commercial officer, marks a critical milestone as we build out our commercial organization and prepare for a potential product launch of MDMA-assisted therapy if approved by the FDA,” said Amy Emerson, chief executive officer of Lykos Therapeutics. “In addition, Coy, a seasoned professional who has successfully led access and reimbursement efforts for more than 30 product launches, joins to establish a patient-access program in advance of a potential FDA approval of MDMA-assisted therapy.”
As the lead for the company’s commercial strategy and operations, Rosenthal will have an initial focus on the potential launch of MDMA capsules – if approved by the U.S. Food and Drug Administration – to be used in combination with psychological intervention. FDA approval could come as soon as August.
Rosenthal brings more than 25 years of pharmaceutical experience introducing innovative therapies, according to Lykos.
Most recently, Rosenthal was head of the U.S. neuroscience sales and marketing for Otsuka, where she was responsible for leading, developing and executing effective commercial strategies for Otsuka’s U.S. business with an organization of nearly 1,000 people and sales approaching $1.5 billion.
Before joining Otsuka U.S., Rosenthal was general manager of Otsuka Canada for eight years, during which time she led the early asset and development team for Otsuka global marketing. Before Otsuka, Rosenthal spent 18 years at Bristol-Myers Squibb in roles with increasing levels of responsibility.
Rosenthal has a bachelor’s degree in anatomical sciences and a master’s degree in anatomy and cell biology, both from McGill University of Montreal.
Stout brings more than 25 years of experience as a leader in the biopharmaceutical industry, according to Lykos. He has established reimbursement, distribution and patient-support programs to help advance patient access in the United States for important medications across multiple therapeutic areas with high unmet needs and social stigma, Lykos noted.
Before joining Lykos, Stout served as the senior vice president of patient advocacy and policy at Brii Biosciences for two and a half years. Before Brii Biosciences, Stout had a 17-year tenure at Gilead, where he last served as VP of market access strategy and account management.
In addition to his expertise in drug coverage, innovative payment models and patient-support programs, Stout has successfully led access and reimbursement efforts for more than 30 product launches, according to Lykos.
Stout received his bachelor’s degree in psychology and master’s degree in social work from the University of Alabama, and he earned a doctorate in social work from Simmons University.
This past December, Lykos submitted a new-drug application to the U.S. Food and Drug Administration for MDMA-assisted therapy.
In February, the FDA granted the application “priority review.” When the FDA grants priority-review status, the agency has six months to conclude its review process.